As another example, the broad effects of genetic mimicry of tyrosine kinase 2 (TYK2) inhibition (targeted by deucravacitinib) on ∼1500 outcomes among ∼340 000 participants of the UK Biobank study were recently examined in an MR-PheWAS.117 The study showed that TYK2 inhibition instrumented by a variant in the TYK2 gene was, as expected, effective in reducing the risk of psoriasis and other autoimmune diseases but was associated with potential adverse effects such as increased risk of prostate and breast cancer.117. The gene discussed is TYK2; the disease is breast carcinoma.